Deciphera doses first patient in early-stage DCC-3116 cancer trial
- Deciphera Pharmaceuticals (NASDAQ:DCPH) announces that it has dosed the first patient in the company’s early-stage trial of DCC-3116 in patients with advanced or metastatic tumors with a mutant RAS or RAF gene.
- The Phase 1, multicenter, open-label, first-in-human…
